COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial
COVAC-2, a recombinant protein vaccine, demonstrated a favorable safety profile and strong immune responses as a booster in previously vaccinated adults.
Asset / Drug
Drug and asset intelligence for COVAC-2 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.